High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
the purpose of this study is to evaluate the efficacy and safety of high-dose，pulsatile
Erlotinib/Gefitinib in advanced non small cell lung cancer (NSCLC) patients after failure of
standard dose EGFR-TKIs（Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors）